Low Responsiveness to Clopidogrel Increases Risk among CKD Patients Undergoing Coronary Intervention
Authors:
- Suzanne Fateh-MoghadamSFSuzanne Fateh-Moghadam
- Christian BischofsCBChristian Bischofs
- Winston BanyaWBWinston Banya
- Karin MüllerKMKarin Müller
- Boris BigalkeBBBoris Bigalke
- Konstantinos StellosKSKonstantinos Stellos
- Andreas E. MayAMAndreas E. May
- Marcus FlatherMFMarcus Flather
- Meinrad GawazMGMeinrad Gawaz
- Tobias GeislerTGTobias Geisler
- 1 April 2011
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 22 (4) , 627-633
Abstract
Patients with CKD are at higher risk for major events after percutaneous coronary intervention (PCI) compared with subjects with normal renal function. The aims of this study were to evaluate responsiveness to clopidogrel in patients with CKD and to examine the effect of antiplatelet drug response on post-PCI outcome. We retrospectively evaluated a consecutive cohort of 1567 patients with symptomatic coronary artery disease undergoing PCI, 648 (41%) of whom had stage 3 to 5 CKD. We assessed responsiveness to clopidogrel by ADP-induced platelet aggregation after oral administration of a 600-mg clopidogrel loading dose and 100 mg of aspirin. In a multivariate survival analysis that included 1335 (85%) of the cohort, stage 3 to 5 CKD and low response to clopidogrel were independent predictors of the primary end point (composite of myocardial infarction, ischemic stroke, and death within 1 year). In summary, a low response to clopidogrel might be an additional risk factor for the poorer outcomes in patients with stage 3 to 5 CKD compared with patients with better renal function.Keywords
This publication has 45 references indexed in Scilit:
- A Comparison of Clopidogrel Responsiveness in Patients With Versus Without Chronic Renal FailureThe American Journal of Cardiology, 2009
- Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)The American Journal of Cardiology, 2009
- Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of Cardiology National Cardiovascular Data Registry)The American Journal of Cardiology, 2009
- The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) TrialAmerican Heart Journal, 2008
- Prevalence and Predictors of Cardiovascular Calcium in Chronic Kidney Disease (from the Prospective Longitudinal RRI-CKD Study)The American Journal of Cardiology, 2006
- Impact of renal insufficiency on outcome after contemporary percutaneous coronary interventionAmerican Heart Journal, 2006
- Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary interventionClinical Nephrology, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Plasma thrombopoietin levels in patients with chronic renal failureThe Hematology Journal, 2002
- PROSTACYCLIN-LIKE ACTIVITY AND BLEEDING IN RENAL FAILUREThe Lancet, 1977